Abstract : Lecanemab in Early Alzheimer’s Disease | NEJMCONCLUSIONS
Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer’s disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455. opens in new tab.)
Maybe a step forward, but not a very big one, IMO.
Abstract : Lecanemab in Early Alzheimer’s Disease |...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 25268416 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 18128695 | 9 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| ATH (ASX) Chart |